Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maximilian Merz

Showing results (101-110 of 127) with videos related to

Pageof 13
Sort By:
Bone Marrow Transplantation|December 5, 2024
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myelomaNora Grieb, Alexander Oeser, Maximilian Ferle, et al.
Transfusion|July 29, 2025
Impact of cellular composition and T-cell senescence of mononuclear cell concentrates on the manufacturing process of chimeric antigen receptor (CAR) T-cellsVladan Vučinić, Theresa Tumewu, Mandy Brückner, et al.
Transplantation and Cellular Therapy|June 9, 2021
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple MyelomaSarah A Holstein, Nizar Bahlis, P Leif Bergsagel, et al.
Blood|June 12, 2025
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRSTMaximilian Merz, Nico Gagelmann, Samih Smaili, et al.
Leukemia|March 25, 2026
Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myelomaJohannes Waldschmidt, David Fandrei, Judith S Hecker, et al.
Leukemia|November 17, 2021
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Hemasphere|April 6, 2026
Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myelomaThomas C Wiemers, Michael Rade, Nora Grieb, et al.
Blood Cancer Discovery|October 23, 2024
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple MyelomaDavid Fandrei, Sabine Seiffert, Michael Rade, et al.
Leukemia|July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Blood|January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialMarc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.
Pageof 13

Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Bone Marrow Transplantation|December 5, 2024
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myelomaNora Grieb, Alexander Oeser, Maximilian Ferle, et al.
Transfusion|July 29, 2025
Impact of cellular composition and T-cell senescence of mononuclear cell concentrates on the manufacturing process of chimeric antigen receptor (CAR) T-cellsVladan Vučinić, Theresa Tumewu, Mandy Brückner, et al.
Transplantation and Cellular Therapy|June 9, 2021
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple MyelomaSarah A Holstein, Nizar Bahlis, P Leif Bergsagel, et al.
Blood|June 12, 2025
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRSTMaximilian Merz, Nico Gagelmann, Samih Smaili, et al.
Leukemia|March 25, 2026
Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myelomaJohannes Waldschmidt, David Fandrei, Judith S Hecker, et al.
Leukemia|November 17, 2021
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Hemasphere|April 6, 2026
Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myelomaThomas C Wiemers, Michael Rade, Nora Grieb, et al.
Blood Cancer Discovery|October 23, 2024
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple MyelomaDavid Fandrei, Sabine Seiffert, Michael Rade, et al.
Leukemia|July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Blood|January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialMarc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.
Pageof 13